title: Biological and therapeutic aspects of proliferative vitreoretinopathy.
abstract: Conventional vitreoretinal surgery for proliferative vitreoretinopathy is unsatisfactory despite numerous innovations over the past 20 years. Silicone oil injections in this series resulted in 70% reattachment of these end-stage cases, but within twelve months over 90% had no useful visual result. The development of an in vitro model for 3-dimensional culture of cells has allowed evaluation of numerous potential drugs with anti-proliferative or anti-contractile activities. Amongst these, taxol has shown the most promise. There remain, however, doubts about possible long-term toxicity to the optic nerve and retina. It is concluded that a more physiological vitreous substitute and more specific anti-proliferative or anti-contractile pharmacological agents are needed.
mesh_terms: D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002829:Choroid / Q000166:cytology / Q000637:transplantation; D003094:Collagen; D005128:Eye Diseases / Q000188:drug therapy / Q000601:surgery; D005347:Fibroblasts / Q000166:cytology; D005782:Gels; D006801:Humans; D017239:Paclitaxel; D012164:Retinal Diseases / Q000188:drug therapy / Q000601:surgery*; D012827:Silicone Oils; D014268:Trifluoperazine / Q000494:pharmacology; D014822:Vitreous Body / Q000502:physiology
chemical_list: D000470:Alkaloids; D005782:Gels; D012827:Silicone Oils; D014268:Trifluoperazine; D003094:Collagen; D017239:Paclitaxel